Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 7/20 | 0.47 |
| ▸ | TFPI | P10646 | 4/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437206 | 1.00 | EPHA2 (0.47) | EPHA2TFPICXCR4OPRM1OPRK1 | |
| SCHEMBL31437166 | 0.96 | OPRM1 (0.45) | EPHA2TFPIOPRM1OPRK1NMUR2 | |
| SCHEMBL31437184 | 0.93 | NMUR2 (0.45) | EPHA2TFPIOPRM1OPRK1NMUR2 | |
| SCHEMBL31437163 | 0.89 | PRCP (0.44) | EPHA2CXCR4NMUR2NMUR1 | |
| SCHEMBL31437156 | 0.88 | PTPN1 (0.43) | EPHA2CXCR4NMUR2NMUR1 | |
| SCHEMBL31437208 | 0.86 | PRCP (0.45) | EPHA2OPRM1OPRK1 | |
| SCHEMBL31467773 | 0.86 | RAMP3 (0.51) | EPHA2TFPICXCR4 | |
| SCHEMBL31467763 | 0.85 | EPHA2 (0.48) | EPHA2TFPICXCR4 | |
| SCHEMBL31467760 | 0.84 | PRCP (0.45) | EPHA2OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL31437193 | 0.82 | PRCP (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037993-A1 | DOSAGE FORM FOR PEPTIDE AGENTS | MAJEWSKI FILIP (PL) | 2025-02-20 | — | — | WO | disclosed |